Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Studied in peopleStub

Melanotan II

Melanocortin receptor agonist

A cyclic analogue of alpha-MSH that acts on several melanocortin receptors. It was studied in early trials and is not a licensed medicine.

Reconstitution calculator

At a glance

Studied in people

There are published studies in people. It is not a licensed medicine in the United States or the European Union.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies: Melanotan II

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

624
papers on PubMed
182
of them in people
1
randomized trials
34
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Melanotan II itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Melanotan II; no amount here is a recommendation.

Melanotan II: on PubMed

What PubMed held for Melanotan II on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

624
papers
182
in humans
5
clinical trials
1
randomized trials
2012: 17 papers122013: 23 papers2014: 19 papers142015: 17 papers2016: 10 papers162017: 11 papers2018: 18 papers182019: 7 papers2020: 17 papers202021: 18 papers2022: 12 papers222023: 9 papers2024: 9 papers242025: 4 papers2026: 9 papers so far26
Papers per year, 2012 to 2026. The most in one year: 23.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study

    TrialDorr RT, Lines R, Levine N, et al. Life sciences, 1996. PMID 8637402

  2. Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review

    ReviewGhaffari-Rafi A, Samandouras G World neurosurgery, 2020. PMID 31473344

  3. Peptides for male sexual dysfunction: a systematic review of emerging evidence

    ReviewRamez M, Mostafa MM, Mohamed H, et al. The journal of sexual medicine, 2026. PMID 43002584

  4. Exercise-induced metallothionein expression in human skeletal muscle fibres

    TrialPenkowa M, Keller P, Keller C, et al. Experimental physiology, 2005. PMID 15640275

  5. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study

    TrialWessells H, Fuciarelli K, Hansen J, et al. The Journal of urology, 1998. PMID 9679884

  6. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II

    TrialWessells H, Levine N, Hadley ME, et al. International journal of impotence research, 2000. PMID 11035391

  7. Metallothionein in Brain Disorders

    ReviewJuárez-Rebollar D, Rios C, Nava-Ruíz C, et al. Oxidative medicine and cellular longevity, 2017. PMID 29085556

  8. CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists

    StudyTomassi S, Dimmito MP, Cai M, et al. Journal of medicinal chemistry, 2022. PMID 35188390

Search used: ("melanotan II"[tiab] OR "melanotan-II"[tiab] OR "MT-II"[tiab]). Run it on PubMed

Research links

Also in Skin and longevity